DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Fibromyalgia - Pipeline Review, H2 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Fibromyalgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibromyalgia and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Fibromyalgia Overview
- Therapeutics Development
- Pipeline Products for Fibromyalgia - Overview
- Pipeline Products for Fibromyalgia - Comparative Analysis
- Fibromyalgia - Therapeutics under Development by Companies
- Fibromyalgia - Therapeutics under Investigation by Universities/Institutes
- Fibromyalgia Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Fibromyalgia - Products under Development by Companies
- Fibromyalgia - Products under Investigation by Universities/Institutes
- Fibromyalgia - Companies Involved in Therapeutics Development
- Astellas Pharma Inc.
- Daiichi Sankyo Company, Limited
- Merck & Co., Inc.
- SWITCH Biotech LLC
- Theravance Biopharma, Inc.
- Tonix Pharmaceuticals Holding Corp.
- Zynerba Pharmaceuticals, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/wffr4l/fibromyalgia
Related Topics: Immune Disorders Drugs, Musculoskeletal Disorders Drugs
